Fairscale Capital’s ARK Genomic Revolution ETF ARKG Stock Holding History

Fairscale Capital’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$27K	Hold	642	–	–	0.02%	259
2026 Q1	$17K	Hold	642	–	–	0.01%	289
2025 Q4	$18.6K	Hold	642	–	–	0.01%	278
2025 Q3	$17.8K	Hold	642	–	–	0.01%	290
2025 Q2	$15.3K	Hold	642	–	–	0.01%	298
2025 Q1	$13.3K	Hold	642	–	–	0.01%	244
2024 Q4	$15.1K	Hold	642	–	–	0.01%	240
2024 Q3	$16.4K	Hold	642	–	–	0.01%	239
2024 Q2	$17.6K	Buy	+642	New	+$16.2K	0.02%	230

Other funds holding ARKG

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Fairscale Capital's ARKG Position: Q2 2026 in Review

Fairscale Capital held its ARK Genomic Revolution ETF (ARKG) position steady in Q2 2026 at 642 shares worth $27K. The position accounts for 0.02% of the portfolio, ranked #259.

Fairscale Capital first reported a position in ARKG in Q2 2024 and has held it in 9 quarters since. 272 funds tracked by Wall St. Rank hold ARKG as of Q2 2026.

Fairscale Capital held 642 shares of ARK Genomic Revolution ETF worth $27K as of Q2 2026.
Fairscale Capital left its ARK Genomic Revolution ETF share count unchanged in Q2 2026.
ARK Genomic Revolution ETF made up 0.02% of Fairscale Capital's portfolio in Q2 2026, its #259 holding.
Fairscale Capital first reported a position in ARK Genomic Revolution ETF in Q2 2024 and has held it in 9 quarters since.
272 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2026.

Based on Fairscale Capital's 13F filing for Q2 2026, filed 7 Aug 2026.